Basket cover image
15 handpicked stocks

Riding Europe's Airline Recovery

Ryanair's recent doubling of its quarterly profits highlights a significant recovery and pricing power in Europe's budget airline sector. This success signals a broader investment opportunity among low-cost carriers and the supporting travel industry ecosystem.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at juillet 22

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

RYAAY

Ryanair Holdings plc

RYAAY

Current price

$66.08

LUV

Southwest Airlines Co.

LUV

Current price

$31.59

DAL

Delta Air Lines Inc.

DAL

Current price

$60.50

About This Group of Stocks

1

Our Expert Thinking

Ryanair's recent doubling of quarterly profits demonstrates the strong recovery in Europe's travel sector. This success from a market leader suggests favorable conditions across the entire budget airline ecosystem, creating opportunities for low-cost carriers and their supporting businesses.

2

What You Need to Know

This group focuses on the cyclical recovery of European travel, capturing companies that benefit from increased passenger volumes and pricing power. The theme includes budget airlines, regional airports, and travel service providers positioned to benefit from sustained consumer travel demand.

3

Why These Stocks

These stocks were handpicked by professional analysts to capture the ripple effect from strong airline performance. The selection targets companies operating within the budget travel ecosystem that could benefit from the broader recovery in European leisure and business travel.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+29.44%

Group Performance Snapshot

29.44%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 29.44% over the next year.

11 of 15

Stocks Rated Buy by Analysts

11 of 15 assets in this group are rated Buy by professional analysts.

3.7%

Group Growth

This group averaged a 3.7% return last month.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

✈️

Travel Boom in Motion

Post-pandemic travel demand is surging across Europe, with airlines reporting record passenger volumes and the ability to charge premium prices for popular routes.

📈

Pricing Power Advantage

Leading budget carriers like Ryanair are demonstrating strong pricing power, with average fares up 21% while still growing passenger traffic by 4%.

🎯

Ripple Effect Opportunity

When market leaders perform this well, it often signals broader opportunities across the entire travel ecosystem, from airlines to booking platforms to car rentals.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View all Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.